|
FY2021
12 months to Dec 31, 2021
|
FY2020
12 months to Dec 31, 2020
|
|
|---|---|---|
| Collaboration revenue | ||
| Operating expenses: | ||
| Research and development | ||
| General and administrative | ||
| Restructuring charges | ||
| Total operating expenses | ||
| Loss from operations | ||
| Other income: | ||
| Gain on Hit Discovery divestiture | ||
| Interest income | ||
| Other income (expense), net | ||
| Total other income, net | ||
| Loss before taxes | ||
| Income tax expense (benefit) | ||
| Net loss and comprehensive loss | ||
| Accretion of cumulative dividends and issuance costs on Series D redeemable convertible preferred stock | ||
| Net loss allocable to shares of common stock, basic | ||
| Change in fair value attributable to warrants to purchase Series B-3 convertible preferred stock | ||
| Net loss allocable to shares of common stock, diluted | ||
| Net loss allocable to shares of common stock, basic and diluted | ||
| Net loss per share of common stock: | ||
| Basic | ||
| Diluted | ||
| Net loss per share of common stock, basic and diluted | ||
| Weighted-average shares of common stock outstanding, basic and diluted |
Loading...
